1. Home
  2. BLDR vs IONS Comparison

BLDR vs IONS Comparison

Compare BLDR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Builders FirstSource Inc.

BLDR

Builders FirstSource Inc.

HOLD

Current Price

$104.38

Market Cap

12.7B

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$81.07

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLDR
IONS
Founded
1998
1989
Country
United States
United States
Employees
N/A
N/A
Industry
RETAIL: Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7B
13.5B
IPO Year
2005
1996

Fundamental Metrics

Financial Performance
Metric
BLDR
IONS
Price
$104.38
$81.07
Analyst Decision
Buy
Strong Buy
Analyst Count
18
22
Target Price
$134.88
$85.14
AVG Volume (30 Days)
2.1M
1.8M
Earning Date
05-20-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.71
EPS
3.89
N/A
Revenue
$15,190,638,000.00
N/A
Revenue This Year
$2.04
N/A
Revenue Next Year
$5.99
$50.35
P/E Ratio
$27.05
$115.15
Revenue Growth
N/A
N/A
52 Week Low
$94.35
$23.95
52 Week High
$151.03
$86.74

Technical Indicators

Market Signals
Indicator
BLDR
IONS
Relative Strength Index (RSI) 37.09 46.16
Support Level $103.53 $79.78
Resistance Level $119.52 $82.85
Average True Range (ATR) 5.20 2.60
MACD -1.88 -0.40
Stochastic Oscillator 12.07 27.48

Price Performance

Historical Comparison
BLDR
IONS

About BLDR Builders FirstSource Inc.

Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: